Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone44-0-15-3475-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$248.07 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable
Novocure (NASDAQ:NVCR) Frequently Asked Questions
What is Novocure's stock symbol?
Novocure trades on the NASDAQ under the ticker symbol "NVCR."
How were Novocure's earnings last quarter?
Novocure Ltd (NASDAQ:NVCR) announced its earnings results on Thursday, July, 25th. The medical equipment provider reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.06. The medical equipment provider earned $86.70 million during the quarter, compared to the consensus estimate of $78.98 million. Novocure had a negative net margin of 13.84% and a negative return on equity of 31.80%. The business's quarterly revenue was up 41.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. View Novocure's Earnings History.
When is Novocure's next earnings date?
How can I listen to Novocure's earnings call?
Novocure will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for NVCR?
6 brokerages have issued 1-year target prices for Novocure's stock. Their forecasts range from $36.00 to $97.00. On average, they expect Novocure's stock price to reach $72.17 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for Novocure.
What is the consensus analysts' recommendation for Novocure?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.
Has Novocure been receiving favorable news coverage?
News headlines about NVCR stock have been trending somewhat negative on Wednesday, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novocure earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Novocure.
Are investors shorting Novocure?
Novocure saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,400,000 shares, a decline of 7.6% from the August 30th total of 4,760,000 shares. Based on an average daily trading volume, of 854,600 shares, the days-to-cover ratio is currently 5.1 days. Approximately 5.6% of the company's stock are sold short. View Novocure's Current Options Chain.
Who are some of Novocure's key competitors?
Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Cantel Medical (CMD).
What other stocks do shareholders of Novocure own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK).
Who are Novocure's key executives?
Novocure's management team includes the folowing people:
- Asaf Danziger, Chief Executive Officer & Director
- Mike Ambrogi, Chief Operating Officer
- Wilco Groenhuysen, CFO & Chief Accounting Officer
- Eilon D. Kirson, Chief Science Officer, Head-Research & Development
- Uri Weinberg, Vice President-Clinical Development
Who are Novocure's major shareholders?
Novocure's stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.35%), Peregrine Capital Management LLC (0.15%), Essex Investment Management Co. LLC (0.04%), Tuttle Tactical Management (0.03%), Strs Ohio (0.03%) and Polianta Ltd (0.01%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.
Which institutional investors are selling Novocure stock?
NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Essex Investment Management Co. LLC, Envestnet Asset Management Inc. and Crow Point Partners LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.
Which institutional investors are buying Novocure stock?
NVCR stock was purchased by a variety of institutional investors in the last quarter, including Tuttle Tactical Management, Polianta Ltd, Virginia Retirement Systems ET AL, Henry James International Management Inc., Brinker Capital Inc., Alpine Group USVI LLC, Alpine Group USVI LLC and Strs Ohio. View Insider Buying and Selling for Novocure.
How do I buy shares of Novocure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novocure's stock price today?
One share of NVCR stock can currently be purchased for approximately $71.81.
How big of a company is Novocure?
Novocure has a market capitalization of $7.05 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.
What is Novocure's official website?
How can I contact Novocure?
Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at investor[email protected]
MarketBeat Community Rating for Novocure (NASDAQ NVCR)
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
